Table 2 Associations of DMR methylation and patient post-treatment survival.

From: Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia

DMR

HR

95% CI

PFDR

 

HOXA4

3.48

1.71–7.08

0.0445*

 

SLCO3A1

2.43

1.26–4.68

0.0446*

 

MAFB

2.34

1.19–4.59

0.0445*

 

ADAMTS17

2.12

1.10–4.07

0.0607

 

ZNF503

1.96

0.91–4.22

0.1660

 

MYRIP

1.95

1.01–3.74

0.0820

 

CDK6

1.88

0.96–3.66

0.0820

 

BEND6

1.77

0.65–4.84

0.1660

 

DAGLA

1.74

0.79–3.82

0.1390

 
  1. Univariate analysis of post-treatment survival in the ICGC cohort by methylation of the nine CLL-specific DMRs that were identified as differentially expressed following therapeutic intervention and displaying significant correlations between methylation and gene expression. The DMRs are ranked by hazard ratio (HR, with 95% confidence intervals), with significant results (PFDR < 0.05) highlighted in bold and by an asterisk.
Back to article page